Efficacy and Safety of Perampanel as the First Medication for Children with Newly Diagnosed Epilepsy: A Real-World Single-Center Prospective Observational Study - Takeaways - MDSpire

Efficacy and Safety of Perampanel as the First Medication for Children with Newly Diagnosed Epilepsy: A Real-World Single-Center Prospective Observational Study

  • By

  • Huang, Wenmin

  • Cao, Dezhi

  • May 6, 2026

  • 0 min

Share

  • 1

    Perampanel (PER) was evaluated as the initial monotherapy for pediatric epilepsy in a prospective observational study.

  • 2

    The study included 137 patients, with a 1.5% attrition rate and a 5.1% discontinuation rate due to adverse events.

  • 3

    At 12 months, the overall seizure-free rate was 64.1%, with a higher rate of 78.6% in patients with self-limited epilepsy.

  • 4

    Common adverse events included dizziness, drowsiness, and irritability, primarily mild and manageable with dose adjustments.

  • 5

    The findings support the efficacy and safety of PER monotherapy for children with epilepsy, with a notable response rate over time.

Original Source(s)

Efficacy and Safety of Perampanel as the First Medication for Children with Newly Diagnosed Epilepsy: A Real-World Single-Center Prospective Observational Study

  • by Huang, Wenmin , Cao, Dezhi

  • May 6, 2026

Related Content

Recurrent dysplasia epiphysealis hemimelica: a case report and review of the literature

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Feasibility and implementation of a daily safety brief at a children's hospital-in-a-hospital